Stay updated on Pembrolizumab in Renal Cell Carcinoma Adjuvant Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Renal Cell Carcinoma Adjuvant Clinical Trial page.

Latest updates to the Pembrolizumab in Renal Cell Carcinoma Adjuvant Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.0%
- Check19 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed study information regarding the safety and efficacy of pembrolizumab in treating renal cell carcinoma, while adding identifiers and a new revision number.SummaryDifference16%
- Check26 days agoNo Change Detected
- Check34 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
- Check41 days agoChange DetectedThe web page has been updated to version 2.14.3, replacing the previous version 2.14.2.SummaryDifference0.0%
- Check78 days agoChange DetectedThe web page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.5%
- Check92 days agoChange DetectedThe website has updated to revision v2.14.2, noting that some NLM-NCBI services are experiencing heavy traffic, which may impact performance and availability.SummaryDifference0.5%
Stay in the know with updates to Pembrolizumab in Renal Cell Carcinoma Adjuvant Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Renal Cell Carcinoma Adjuvant Clinical Trial page.